Anthracyclines with unusually high activity against cells resist

Details Anthracyclines with unusually high activity against cells resist Anthracyclines with unusually high activity against cells resist

1995-02-27

1997-04-29

Peselev, Elli

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

C07M 1524

Patent

active

056250436

ABSTRACT:
The present disclosure details novel modified anthracyclines, the synthesis thereof, and their use in treating patients with tumors. Preferred aspects of the disclosure involve modified anthracyclines which have an O-substituted aromatic ring on their sugar moiety. Other preferred aspects of the disclosure involve synthesis steps wherein a hydroxyl group on a sugar moiety to be added is blocked with a halo-substituted alkyl group during the process of adding it to an anthracycline ring compound.

REFERENCES:
patent: 4201773 (1980-05-01), Horton et al.
patent: 4327029 (1982-04-01), Bernardi et al.
patent: 4427664 (1984-01-01), Horton et al.
patent: 4537882 (1985-08-01), Horton et al.
patent: 4562177 (1985-12-01), Horton et al.
patent: 4663445 (1987-05-01), Swenton et al.
patent: 4697005 (1987-09-01), Swenton et al.
patent: 4863739 (1989-09-01), Perez-Soler et al.
patent: 4870058 (1989-09-01), Horton et al.
patent: 5132290 (1992-07-01), Priebe et al.
Bodley et al., "N-Alkyl Analogs of Doxorubicin Do Not Inhibit DNA Topoisomerase II," Proc. Ann. Meet. Am. Assoc. Cancer Res., 30:621, Abstract No. 2472, 1989.
Ganapathi et al., "N-Benzyladriamycin-14-valerate Versus Progressively Doxorubicin-Resistant Murine Tumours: Cellular Pharmacology and Characterisation of Cross-Resistance in vitro and in vivo," Br. J. Cancer, 60:819-826, 1989.
Goodman and Gilman's, "The Pharmacological Basis of Therapeutics," Eighth Edition, Pergamon Press, Chapter 52, pp. 1241-1244.
Israel et al., "Amelioration of Adriamycin Toxicity Through Modification of Drug-DNA Binding Properties," Cancer Treatment Reviews, 14:163-167, 1987.
Lothstein et al., "Resistance to N-Benzyladriamycin-14-valerate in Mouse J744.2 Cells: P-Glycoprotein Expression without Reduced N-Benzyladriamycin-14-valerate Accumulation," Cancer Research, 52:3409-3417, 1992.
O'Dwyer et al., "Drug Therapy. Etoposide (VP-16-213). Current Status of an Active Anticancer Drug," The New England Journal of Medicine, 312:692-700, 1985.
Priebe et al., "Novel Anthracycline Antibiotics Deoxygenated at C-4'", Proc. Ann. Meet. Am. Assoc. Cancer Res., 30:575, Abstract No. 2287, 1989.
Remington's Pharmaceutical Sciences, Alfonso R. Gennaro, Editor, Eighteenth Edition, Chapter 61, pp. 1150-1151, 1990.
Cheung et al., "Preparative Synthesis of 2,6-dideoxy-.alpha.-L-lyxo-Hexose (2-Deoxy-.alpha.-L-Fucose) and its D-ribo Epimer (Digitoxose)" Carbohydrate Research 58:139-151, (1977).

Affiliated with

Also associated with

Rating

Anthracyclines with unusually high activity against cells resist does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Anthracyclines with unusually high activity against cells resist, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anthracyclines with unusually high activity against cells resist will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-706858